Sumanta K. Pal: I’m hugely indebted to Matt Galsky, not just for the chance to be a part of this Nature Medicine masterpiece he drove, but to see the joy of my pts doing well years out from chemo/IO without cystectomy.
Sumanta K. Pal, Professor and Co-director of City of Hope’s Kidney Cancer Program, shared a post on X/Twitter:
”I’m hugely indebted to Matt Galsky, not just for the chance to be a part of this Nature Medicine masterpiece he drove, but to see the joy of my pts doing well years out from chemo/IO w/o cystectomy. But not the 1st time Matt has given my pts a gift via our collaboration.
Matt is a visionary. Our 1st (2nd?) collab was on a trial of cis/gem+ipi for mUC. I met a pt in 2014 (well before CPI was SOC) with bowel obstruction from UC; started on Matt’s study & doing brilliantly p 9y. Matt published a biological interrogation of responders in the Journal for ImmunoTherapy of Cancer.
My note to GU oncologist colleagues: If there’s an opportunity to participate in trials proposed by Matt Galsky, take it! The advice I gave to our City of Hope, bladder cancer lead Abhishek Tripathi, who is now enrolling to Matt Galsky‘s neoadjuvant pembrolizumab study. Keep up the amazing work, Matt! ”
For the article click here.
Source: Sumanta K. Pal/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023